Shapiro W R, Young D F
Arch Neurol. 1976 Jul;33(7):494-50. doi: 10.1001/archneur.1976.00500070036007.
Thirty-three patients with malignant glioma were randomly divided into two groups after extensive tumor resection. Those in group A received, every five to eight weeks, a course of chemotherapy consisting of intravenously administered carmustine, 80 mg/sq m/day for three days, and vincristine sulfate, 1.4mg/sq m on days 1 and 8. Patients in group B were treated identically and received radiation therapy (RT) as well, 4,500 rads whole brain plus 1,500 rads to the side of the tumor. The median survival time of group A was 30 weeks, while that of group B was 44.5 weeks, but the overall survival curves were not significantly different. The median survival times exceeded the 17 weeks reported elsewhere in comparable patients not receiving postoperative therapy. Estimates of the quality of survival suggested (1) the two groups were not comparable following randomization, possibly influencing the results; and (2) postoperative radiation and chemotherapy do not increase morbidity and offer a longer period than other treatments during which patients' conditions remain stable or improve.
33例恶性胶质瘤患者在肿瘤广泛切除后被随机分为两组。A组患者每5至8周接受一个疗程的化疗，化疗方案为静脉注射卡莫司汀，80毫克/平方米/天，连用3天，以及硫酸长春新碱，第1天和第8天各1.4毫克/平方米。B组患者接受相同的化疗，并同时接受放射治疗（RT），全脑照射4500拉德，肿瘤部位追加照射1500拉德。A组的中位生存时间为30周，B组为44.5周，但总体生存曲线无显著差异。中位生存时间超过了其他未接受术后治疗的类似患者所报告的17周。生存质量评估表明：（1）随机分组后两组不具有可比性，这可能影响了结果；（2）术后放疗和化疗不会增加发病率，且与其他治疗相比，能使患者病情保持稳定或改善的时间更长。
